Table 1.

Tim3 inhibition

Name of compound	Mechanism of action	Study phase	Company	Trial ID*	Tumour type	Target accrual
Single TIM3 blockade
Sym023	Anti-TIM3 mAb	I	Symphogen A/S	NCT03489343	Solid tumours and lymphoma	48
INCAGN02390	Anti-TIM3 Ab	I	Incyte	NCT03652077	Solid tumours	76
Combination TIM3 blockade
LY3321367 ± LY3300054	Anti-TIM3 ± anti-PD-L1 mAb	I	Eli Lilly	NCT03099109	Solid tumours	196
Sym021 ± Sym023	Anti-PD1 ± anti-TIM3	I	Symphogen	NCT03311412 (arm B)	Solid tumours, lymphoma	102
MBG453 ± PDR001	Anti-TIM3 ± anti-PD1 mAb	I/II	Novartis	NCT02608268	Solid tumours	250
BGB-A425 + Tislelizumab	Anti-TIM3 + anti-PD1 mAb	I/II	BeiGene	NCT03744468	Solid tumours	162
TSR-022 ± TSR-042	Anti-TIM3 ± anti-PD1 mAb	I	Tesaro	NCT02817633	Solid tumours	627
TSR-022 + TSR-042 + chemo	Anti-TIM3 + anti-PD1 + chemo	I	Tesaro	NCT03307785 (parts F, H, I)	Solid tumours	168
Bispecific TIM3 blockade
RO7121661	Anti-PD-1/TIM3 bispecific Ab	I	Hoffmann-La Roche	NCT03708328	Metastatic melanoma and NSCLC	280
LY3415244	Anti-PD-L1/TIM3 bispecific Ab	I	Eli-Lilly	NCT03752177	Solid tumours	117

*Clinicaltrial.gov ID.

Ab, antibody;mAb, monoclonal antibody;TIM3, T-cell immunoglobulin and mucin domain-3;chemo, chemotherapy